Profile data is unavailable for this security.
About the company
Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
- Revenue in USD (TTM)74.23m
- Net income in USD-65.13m
- Incorporated2002
- Employees174.00
- LocationCodexis Inc200 Penobscot DrREDWOOD CITY 94063-4718United StatesUSA
- Phone+1 (650) 421-8100
- Fax+1 (302) 655-5049
- Websitehttps://www.codexis.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Puma Biotechnology Inc | 226.63m | 15.38m | 231.06m | 185.00 | 14.88 | 4.53 | 8.59 | 1.02 | 0.3219 | 0.3219 | 4.74 | 1.06 | 1.10 | 10.95 | 8.13 | 1,225,016.00 | 7.49 | -12.21 | 11.65 | -20.53 | 73.44 | 78.78 | 6.78 | -11.79 | 1.38 | 2.57 | 0.6624 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
P3 Health Partners Inc | 1.27bn | -57.77m | 231.21m | 400.00 | -- | 0.6004 | -- | 0.1826 | -0.6494 | -0.6494 | 13.37 | 1.22 | 1.46 | -- | 13.23 | 3,165,938.00 | -21.46 | -- | -96.06 | -- | 2.50 | 0.1781 | -14.72 | -56.93 | -- | -10.33 | 0.1999 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
AC Immune SA | 16.34m | -59.87m | 233.11m | 133.00 | -- | 1.31 | -- | 14.27 | -0.7085 | -0.7085 | 0.1924 | 1.79 | 0.0803 | -- | 1.92 | 122,859.00 | -29.41 | -18.25 | -31.56 | -19.52 | -- | -- | -366.41 | -148.29 | -- | -89.52 | 0.0213 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
Aldeyra Therapeutics Inc | 0.00 | -30.01m | 234.09m | 10.00 | -- | 2.06 | -- | -- | -0.5080 | -0.5080 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -19.39 | -36.79 | -22.08 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1182 | -- | -- | -- | 39.47 | -- | -- | -- |
Coherus Biosciences Inc | 257.24m | -237.89m | 240.62m | 306.00 | -- | -- | -- | 0.9354 | -2.56 | -2.56 | 2.74 | -1.72 | 0.4633 | 3.14 | 1.39 | 840,666.70 | -42.85 | -21.43 | -74.34 | -29.32 | 38.19 | 79.01 | -92.48 | -36.56 | 1.24 | -4.77 | 1.69 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
Werewolf Therapeutics Inc | 16.22m | -41.58m | 242.05m | 46.00 | -- | 2.05 | -- | 14.92 | -1.09 | -1.09 | 0.4343 | 2.72 | 0.087 | -- | 4.61 | 345,127.70 | -22.31 | -- | -25.22 | -- | -- | -- | -256.33 | -- | -- | -- | 0.2511 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
Codexis Inc | 74.23m | -65.13m | 244.83m | 174.00 | -- | 3.09 | -- | 3.30 | -0.9412 | -0.9412 | 1.07 | 1.12 | 0.4039 | 5.92 | 4.34 | 426,632.20 | -35.43 | -17.13 | -43.38 | -20.23 | 82.29 | 77.29 | -87.73 | -37.04 | 3.63 | -- | 0.2617 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
Agenus Inc | 161.42m | -239.61m | 246.11m | 389.00 | -- | -- | -- | 1.52 | -12.68 | -12.68 | 8.49 | -9.59 | 0.4823 | -- | 170.54 | 414,951.20 | -74.69 | -55.02 | -242.74 | -115.31 | 99.43 | -- | -154.88 | -102.92 | -- | -1.25 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
Eliem Therapeutics Inc | 0.00 | -35.12m | 250.99m | 9.00 | -- | 2.30 | -- | -- | -1.31 | -1.31 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -28.61 | -- | -29.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
Acrivon Therapeutics Inc | 0.00 | -60.39m | 251.33m | 58.00 | -- | 1.51 | -- | -- | -2.73 | -2.73 | 0.00 | 5.38 | 0.00 | -- | -- | 0.00 | -37.80 | -- | -40.30 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
Century Therapeutics Inc | 1.37m | -133.47m | 251.86m | 152.00 | -- | 1.11 | -- | 183.84 | -2.22 | -2.22 | 0.0227 | 2.74 | 0.0034 | -- | -- | 9,013.16 | -33.17 | -- | -35.08 | -- | -- | -- | -9,742.41 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
Foghorn Therapeutics Inc. | 33.90m | -92.95m | 252.96m | 116.00 | -- | -- | -- | 7.46 | -2.21 | -2.21 | 0.8046 | -2.29 | 0.108 | -- | -- | 292,206.90 | -29.61 | -31.35 | -35.75 | -35.69 | -- | -- | -274.23 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
Fennec Pharmaceuticals Inc | 21.25m | -16.05m | 255.28m | 36.00 | -- | -- | -- | 12.01 | -0.6042 | -0.6042 | 0.7994 | -0.43 | 0.79 | 0.9217 | 4.10 | -- | -59.64 | -73.43 | -77.06 | -84.32 | 94.08 | -- | -75.50 | -383.28 | 3.27 | -3.90 | 1.63 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
Metagenomi Inc | 44.76m | -68.26m | 258.18m | 236.00 | -- | -- | -- | 5.77 | -1.82 | -1.82 | 1.19 | 5.73 | -- | -- | -- | 189,644.10 | -- | -- | -- | -- | -- | -- | -152.50 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
G1 Therapeutics Inc | 84.04m | -30.59m | 260.36m | 100.00 | -- | 9.38 | -- | 3.10 | -0.6146 | -0.6146 | 1.55 | 0.531 | 0.6367 | 0.4852 | 6.07 | 840,410.00 | -23.18 | -47.06 | -30.95 | -52.64 | 91.89 | -- | -36.40 | -268.59 | 2.55 | -3.31 | 0.6084 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Dec 2023 | 5.13m | 7.30% |
Nantahala Capital Management LLCas of 31 Dec 2023 | 4.59m | 6.53% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 4.10m | 5.84% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 4.06m | 5.78% |
Baillie Gifford & Co.as of 31 Mar 2024 | 3.45m | 4.90% |
Opaleye Management, Inc.as of 31 Dec 2023 | 3.05m | 4.33% |
Telemark Asset Management LLCas of 31 Dec 2023 | 2.70m | 3.84% |
Casdin Capital LLCas of 31 Dec 2023 | 2.00m | 2.85% |
Geode Capital Management LLCas of 31 Dec 2023 | 1.51m | 2.15% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.49m | 2.11% |